更新于：2024-11-30
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2024-11-30
概要
基本信息
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
8
项与 培哚普利吲达帕胺 相关的临床试验培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
培哚普利吲达帕胺片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）、口服给药、两制剂、两序列、两周期、交叉的人体生物等效性试验
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
167
项与 培哚普利吲达帕胺 相关的文献（医药）2024-12-01JOURNAL OF HYPERTENSION
Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial
Review
作者: Hamet, Pavel ; Mancia, Giuseppe ; Poulter, Neil ; Wang, Nelson ; Chalmers, John ; Harrap, Stephen ; Grobbee, Diederick E. ; Harris, Katie ; Marre, Michel ; Woodward, Mark
The Action in Diabetes and Vascular disease: preterAx and diamicroN Controlled Evaluation (ADVANCE) trial investigated the effects of intensive blood pressure (BP) lowering using a fixed combination of perindopril-indapamide versus placebo in type 2 diabetes (T2D). The study showed that combination perindopril-indapamide had significant benefits in reducing cardiovascular, renal, and mortality events, with consistent relative risk reductions across different patient subgroups. Secondary analyses of ADVANCE have identified novel risk markers in T2D including cessation of BP lowering therapy, absent peripheral pulses and cardiac biomarkers to name a few. ADVANCE also shed light on practical aspects of hypertension management, including the limitations of office BP, tolerability of combination BP lowering therapy across the range of BP levels and the interpretation of changes in serum creatinine after treatment initiation. This review article summarizes the findings of ADVANCE and its subsequent substudies, which have been foundational in our understanding of BP management and the use of combination BP lowering therapy in T2D.
2024-12-01DIABETES OBESITY & METABOLISM
Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study
Article
作者: Poulter, Neil ; Harrap, Stephen ; Woodward, Mark ; Hamet, Pavel ; Mancia, Giuseppe ; Harris, Katie ; Marre, Michel ; Chalmers, John ; Af Geijerstam, Peder ; Pikkemaat, Miriam
Abstract:
Aim:
Whether apolipoproteins (apolipoprotein A1, apolipoprotein B, apolipoprotein B/apolipoprotein A1 [ApoB/ApoA1] ratio) or very‐low‐density lipoprotein (VLDL) cholesterol are better risk predictors than established lipid risk markers, and whether there are sex differences, is uncertain, both in general populations and in patients with diabetes. The aim of this study was to assess the association between established risk markers, apolipoproteins and the risk of macro‐ and microvascular disease and death in a large study of women and men with diabetes and to assess the potential sex differences in the associations.
Materials and Methods:
Established lipid risk markers were studied in 11 140 individuals with type 2 diabetes from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified‐Release Controlled Evaluation (ADVANCE) trial, and apolipoproteins (A1, B, ApoB/ApoA1 ratio) and VLDL cholesterol from nuclear magnetic resonance (NMR) lipid analyses in biobanked samples from 3586 individuals included in the ADVANCE case‐cohort study (ADVANCE CC). Primary outcomes were major macro‐ and microvascular events and death. Cox proportional hazards models adjusted for confounders were used to quantify the associations (hazard ratio [HR] and 95% confidence intervals [CIs]) between established lipid risk markers and apolipoproteins with study outcomes. To address potential effect modification by sex, we investigated the association between the lipid risk markers and outcomes in subgroup analyses by sex.
Results:
There was a lower risk of macrovascular complications for high‐density lipoprotein (HDL) cholesterol (HR [95%CI] 0.88 [0.82–0.95]), a higher risk for total cholesterol (1.10 [1.04–1.17]), low‐density lipoprotein (LDL) cholesterol (1.15 [1.08–1.22]), non‐HDL cholesterol (1.13 [1.07–1.20]) and the total cholesterol/HDL ratio (1.20 [1.14–1.27]) but no significant associations with triglycerides from ADVANCE. There was a higher risk of macrovascular complications for the ApoB/ApoA1 ratio (1.13 [1.03–1.24]) from the ADVANCE CC. Only the ApoB/ApoA1 ratio (1.19 [1.06–1.34]), but none of the established lipid risk markers, was associated with a higher risk of microvascular complications. There were no statistically significant sex differences for any of the established lipid risk markers or apolipoproteins with any outcome. Using C‐statistics and net reclassification improvement (NRI) did not detect significant improvement in predicting all outcomes by adding lipids or apolipoproteins to the models with confounding factors only.
Conclusions/Interpretation:
All established lipid risk markers, except triglycerides, were predictors of macrovascular complications, but not microvascular complications, in patients with type 2 diabetes. The ApoB/ApoA1 ratio was associated with major macro‐ and microvascular complications, but there was no evidence that apolipoproteins are better than established lipid risk markers in predicting cardiovascular complications in patients with type 2 diabetes.
2024-05-01Diabetes care
Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study
Article
作者: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Warren, Rachel A ; Chalmers, John ; Selvin, Elizabeth ; Rimm, Eric B ; Levy, Andrew P ; Lavallée, Samantha K ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
OBJECTIVE:
Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies.
RESEARCH DESIGN AND METHODS:
Haptoglobin phenotype was measured in available samples from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) biomarker case-cohort study. Weighted multivariable-adjusted Cox regression models were used to evaluate the association between intensive glycemic control (HbA1c target of ≤6.5%) versus standard therapy (based on local guidelines) and major CAD events among participants with (n = 1,327) and without (n = 2,077) the Hp2-2 phenotype separately and within prespecified stratifications by sex, race, previous cardiovascular disease (CVD), diabetes duration, and HDL-cholesterol.
RESULTS:
While the hazard ratios (HRs) were in the hypothesized differing directions, compared with standard therapy, intensive glycemic control was not significantly associated with risk of CAD events among participants without (1.04, 95% CI 0.82–1.32) or with (0.84, 0.63–1.14, Pinteraction = 0.27) the Hp2-2 phenotype overall. Intensive therapy was associated with lower CAD risk among participants with the Hp2-2 phenotype who had no previous CVD (0.47, 0.29–0.76, Pinteraction = 0.01).
CONCLUSIONS:
Our findings suggest that intensive glycemic control contributes to the prevention of major CAD events among ADVANCE participants with the Hp2-2 phenotype and no previous CVD and are in alignment with our hypothesis that intensive glycemic control may be beneficial in a subset of people with the Hp2-2 phenotype.
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 9,195 | (³30% decrease in UACR) | 積夢廠餘範醖網網齋蓋(鑰餘膚鏇艱窪鑰膚廠顧): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | ||
(<30% decrease to <30% increase in UACR) | |||||||
临床3期 | 11,140 | (Normal cognitive function) | 簾襯鏇艱壓夢構窪簾簾(鏇齋蓋壓繭醖鏇糧顧鏇): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用